SPL7013 in VIRALEZE virucidal against influenza A and B

• The broad-spectrum antiviral agent in VIRALEZE™ nasal spray, SPL7013, achieved 95% and 99.7% reduction of virus infectivity against the two most significant influenza viruses, A and B, respectively • Influenza A and B viruses are responsible for seasonal epidemics of influenza, and influenza A viruses are known to cause flu pandemics • SPL7013 demonstrated irreversible virucidal properties again